<div id="subtitle">FDA: Review of data from 3 studies finds no proof Vytorin causes cancer, as was suspected</div><div><p>There's no evidence Merck & Co.'s blockbuster cholesterol drug Vytorin causes cancer, federal regulators said Tuesday. They reviewed reams of data after a patient study last year ...

<div><p>A new study has cast fresh doubt on the effectiveness of Zetia, a cholesterol drug produced by US pharmaceuticals giant Merck.</p><p>Ezetimibe, marketed as Zetia and supposed to target "bad cholesterol" (LDL) was less effective in reducing deposits in the carotid arteries than niacin, sold as Niaspan, which ...

<div><p>ORLANDO, Florida (Reuters) - The good news for Merck & Co's Zetia cholesterol fighter is that doctors do not seem unduly concerned about its latest setback in a clinical trial. The bad news is they think patient anxiety will cause its sales to drop anyway.</p><p>Physicians interviewed ...

<div><p>A new study raises fresh concerns about Zetia and its cousin, Vytorin — drugs still taken by millions of Americans to lower cholesterol, despite questions raised last year about how well they work.</p><p>In the study, Zetia failed to shrink buildups in artery walls while a rival drug, Niaspan ...